Literature DB >> 24416578

Clinical and technological transition in breast cancer.

Philip Poortmans1, Hugo Marsiglia2, Manuel De Las Heras3, Manuel Algara4.   

Abstract

This article is a summary of the conference "Clinical and technological transition in breast cancer" that took place in the Congress of the Spanish Society of Radiation Oncology, placed in Vigo (Spain) on June 21, 2013. Hugo Marsiglia and Philip Poortmanns were the speakers, the first discussed about "Clinical and technological transition" and the second about "EORTC clinical trials and protocols".

Entities:  

Keywords:  Breast cancer; Clinical trial; Radiotherapy; Technological

Year:  2013        PMID： 24416578      PMCID： PMC3863171          DOI： 10.1016/j.rpor.2013.08.002

Source DB:  PubMed          Journal:  Rep Pract Oncol Radiother        ISSN： 1507-1367


  45 in total

1.  Elucidating the role of chest wall irradiation in 'intermediate-risk' breast cancer: the MRC/EORTC SUPREMO trial.

Authors:  I H Kunkler; P Canney; G van Tienhoven; N S Russell
Journal:  Clin Oncol (R Coll Radiol)       Date:  2008-02       Impact factor: 4.126

Review 2.  Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials.

Authors:  M Clarke; R Collins; S Darby; C Davies; P Elphinstone; V Evans; J Godwin; R Gray; C Hicks; S James; E MacKinnon; P McGale; T McHugh; R Peto; C Taylor; Y Wang
Journal:  Lancet       Date:  2005-12-17       Impact factor: 79.321

3.  Breast conserving therapy versus mastectomy for stage I-II breast cancer: 20 year follow-up of the EORTC 10801 phase 3 randomised trial.

Authors:  Saskia Litière; Gustavo Werutsky; Ian S Fentiman; Emiel Rutgers; Marie-Rose Christiaens; Erik Van Limbergen; Margreet H A Baaijens; Jan Bogaerts; Harry Bartelink
Journal:  Lancet Oncol       Date:  2012-02-27       Impact factor: 41.316

4.  New perspectives in radiation oncology: Young radiation oncologist point of view and challenges.

Authors:  Jose Luis Lopez Guerra; Nicolas Isa; Michelle M Kim; Celine Bourgier; Hugo Marsiglia
Journal:  Rep Pract Oncol Radiother       Date:  2012-08-09

5.  Nomogram to predict ipsilateral breast relapse based on pathology review from the EORTC 22881-10882 boost versus no boost trial.

Authors:  Erik van Werkhoven; Guus Hart; Harm van Tinteren; Paula Elkhuizen; Laurence Collette; Philip Poortmans; Harry Bartelink
Journal:  Radiother Oncol       Date:  2011-08-05       Impact factor: 6.280

6.  Do results of the EORTC dummy run predict quality of radiotherapy delivered within multicentre clinical trials?

Authors:  A Fairchild; L Collette; C W Hurkmans; B Baumert; D C Weber; A Gulyban; P Poortmans
Journal:  Eur J Cancer       Date:  2012-07-04       Impact factor: 9.162

7.  Quality assurance of the EORTC Trial 22881/10882: boost versus no boost in breast conserving therapy. An overview.

Authors:  G van Tienhoven; B J Mijnheer; H Bartelink; D G González
Journal:  Strahlenther Onkol       Date:  1997-04       Impact factor: 3.621

8.  Survival after partial breast brachytherapy in elderly patients with nonmetastatic breast cancer.

Authors:  Nengliang Yao; Heath B Mackley; Roger T Anderson; Abram Recht
Journal:  Brachytherapy       Date:  2013-03-07       Impact factor: 2.362

9.  Predictors of the risk of fibrosis at 10 years after breast conserving therapy for early breast cancer: a study based on the EORTC Trial 22881-10882 'boost versus no boost'.

Authors:  Sandra Collette; Laurence Collette; Tom Budiharto; Jean-Claude Horiot; Philip M Poortmans; Henk Struikmans; Walter Van den Bogaert; Alain Fourquet; Jos J Jager; Willem Hoogenraad; Rolf-Peter Mueller; John Kurtz; David A L Morgan; Jean-Bernard Dubois; Emile Salamon; Rene Mirimanoff; Michel Bolla; Marleen Van der Hulst; Carla C Wárlám-Rodenhuis; Harry Bartelink
Journal:  Eur J Cancer       Date:  2008-08-29       Impact factor: 9.162

Review 10.  Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast.

Authors:  C Correa; P McGale; C Taylor; Y Wang; M Clarke; C Davies; R Peto; N Bijker; L Solin; S Darby
Journal:  J Natl Cancer Inst Monogr       Date:  2010
View more
  7 in total

1.  Estimation of optimal matching position for orthogonal kV setup images and minimal setup margins in radiotherapy of whole breast and lymph node areas.

Authors:  Marko Laaksomaa; Mika Kapanen; Tanja Skyttä; Seppo Peltola; Simo Hyödynmaa; Pirkko-Liisa Kellokumpu-Lehtinen
Journal:  Rep Pract Oncol Radiother       Date:  2014-07-15

2.  Adjuvant intraoperative radiotherapy for selected breast cancers in previously irradiated women: Evidence for excellent feasibility and favorable outcomes.

Authors:  Gladys Blandino; Marina Guenzi; Liliana Belgioia; Elisabetta Bonzano; Elena Configliacco; Elena Tornari; Francesca Cavagnetto; Davide Bosetti; Alessandra Fozza; Daniele Friedman; Renzo Corvò
Journal:  Rep Pract Oncol Radiother       Date:  2017-05-05

3.  TES was epigenetically silenced and suppressed the epithelial-mesenchymal transition in breast cancer.

Authors:  Yang Yongbin; Li Jinghua; Zhao Zhanxue; Zang Aimin; Jia Youchao; Shang Yanhong; Jiao Manjing
Journal:  Tumour Biol       Date:  2014-08-15

4.  Why do we need irradiation of internal mammary lymph nodes in patients with breast cancer: Analysis of lymph flow and radiotherapy studies.

Authors:  Novikov Sergey Nikolaevich; Kanaev Sergey Vasilevich
Journal:  Rep Pract Oncol Radiother       Date:  2016-10-22

5.  Volumetric modulated arc therapy for synchronous bilateral whole breast irradiation - A case study.

Authors:  Jan Seppälä; Janne Heikkilä; Kimmo Myllyoja; Kristiina Koskela
Journal:  Rep Pract Oncol Radiother       Date:  2015-06-15

6.  MiR-217 Promotes Tumor Proliferation in Breast Cancer via Targeting DACH1.

Authors:  Qiang Zhang; Yonghui Yuan; Jianchun Cui; Tingting Xiao; Daqing Jiang
Journal:  J Cancer       Date:  2015-01-01       Impact factor: 4.207

7.  miR-217-5p suppresses epithelial-mesenchymal transition and the NF-κB signaling pathway in breast cancer via targeting of metadherin.

Authors:  Lixian Yang; Shuo Liu; Liu Yang; Bin Xu; Meiqi Wang; Xiangshun Kong; Zhenchuan Song
Journal:  Oncol Lett       Date:  2022-03-23       Impact factor: 2.967
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.